Collaborative Arrangement	9 Months Ended
Jun. 30, 2020
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangement	3. Collaborative Arrangement Under the Abbott Agreement, Abbott will have exclusive worldwide commercialization rights for the SurVeil DCB to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (“AV”) fistula drug-coated balloon (“DCB”) products. The below-the-knee DCB, our Sundance^TM DCB, is currently in pre-clinical development. A first-in-human clinical study has been completed for the AV fistula DCB, our Avess^TM DCB, and Abbott has informed the Company that it has elected not to negotiate for distribution rights for this product. Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. and European Union regulatory clearances for the SurVeil DCB, including completion of the ongoing TRANSCEND pivotal clinical trial. Abbott and Surmodics participate on a joint development committee charged with providing guidance on the Company’s clinical and regulatory activities with regard to the SurVeil DCB product. To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity. Under the Abbott Agreement, the Company has received payments totaling $45.8 million which consisted of the following: $25 million upfront fee in fiscal 2018, $10.0 million milestone payment in the fourth quarter of fiscal 2019, and $10.8 million milestone payment in the third quarter of fiscal 2020. The Company may receive up to $45 million of additional payments under the Abbott Agreement upon achievement of certain clinical and regulatory milestones. Revenue recognized from the Abbott agreement totaled $7.6 million and $2.0 million in the three months ended June 30, 2020 and 2019, respectively, and $10.4 million and $5.9 million in the nine months ended June 30, 2020 and 2019, respectively. Revenue recognized from the Abbott Agreement, which was included in the respective beginning of fiscal year balances of deferred revenue in the consolidated balance sheets, totaled $3.7 million and $5.9 million for the nine months ended June 30, 2020 and 2019, respectively. As of June 30, 2020 and September 30, 2019, deferred revenue from the upfront and milestone payments received of $17.5 million and $17.1 million, respectively, was recorded in the condensed consolidated balance sheets. Upon the commercialization of the SurVeil DCB, Surmodics will be responsible for the manufacture and supply of clinical and commercial quantities of the product. Revenue from these product sales, including a per-unit transfer price and a share of net profits resulting from third-party sales by Abbott, will be recognized when these products are shipped and control is transferred to the customer.

Collaborative Arrangement

9 Months Ended

Jun. 30, 2020

Organization Consolidation And Presentation Of Financial Statements [Abstract]

3. Collaborative Arrangement

Under the Abbott Agreement, Abbott will have exclusive worldwide commercialization rights for the SurVeil DCB to treat the superficial femoral artery, which is currently being evaluated in a U.S. pivotal clinical trial. Separately, Abbott also received options to negotiate agreements for Surmodics' below-the-knee and arteriovenous (“AV”) fistula drug-coated balloon (“DCB”) products. The below-the-knee DCB, our Sundance^TM DCB, is currently in pre-clinical development. A first-in-human clinical study has been completed for the AV fistula DCB, our Avess^TM DCB, and Abbott has informed the Company that it has elected not to negotiate for distribution rights for this product. Surmodics is responsible for conducting all necessary clinical trials and other activities required to achieve U.S. and European Union regulatory clearances for the SurVeil DCB, including completion of the ongoing TRANSCEND pivotal clinical trial. Abbott and Surmodics participate on a joint development committee charged with providing guidance on the Company’s clinical and regulatory activities with regard to the SurVeil DCB product.

To account for the Abbott Agreement, the Company applied the guidance in ASC Topic 808 (Collaborative Arrangements) as the parties are active participants and are exposed to significant risks and rewards dependent on commercial success of the collaborative activity.

Under the Abbott Agreement, the Company has received payments totaling $45.8 million which consisted of the following: $25 million upfront fee in fiscal 2018, $10.0 million milestone payment in the fourth quarter of fiscal 2019, and $10.8 million milestone payment in the third quarter of fiscal 2020. The Company may receive up to $45 million of additional payments under the Abbott Agreement upon achievement of certain clinical and regulatory milestones. Revenue recognized from the Abbott agreement totaled $7.6 million and $2.0 million in the three months ended June 30, 2020 and 2019, respectively, and $10.4 million and $5.9 million in the nine months ended June 30, 2020 and 2019, respectively. Revenue recognized from the Abbott Agreement, which was included in the respective beginning of fiscal year balances of deferred revenue in the consolidated balance sheets, totaled $3.7 million and $5.9 million for the nine months ended June 30, 2020 and 2019, respectively. As of June 30, 2020 and September 30, 2019, deferred

revenue from the upfront and milestone payments received of $17.5 million and $17.1 million, respectively, was recorded in the condensed consolidated balance sheets. Upon the commercialization of the SurVeil DCB, Surmodics will be responsible for the manufacture and supply of clinical and commercial quantities of the product. Revenue from these product sales, including a per-unit transfer price and a share of net profits resulting from third-party sales by Abbott, will be recognized when these products are shipped and control is transferred to the customer.